We’ve reinvented business process outsourcing.

See HowClose
Evolve Devices
Evolve

There was a time, when a phone was just a phone. Then almost overnight it became a camera, computer, flashlight, compass and entertainment center. Now, you rely on it for almost anything you need. Imagine if this were our industry. Imagine if all your outsourced services were under one roof. We did.

Learn More

DOHMEN NEWS

Learn what's happening in the world of Dohmen and our clients
February 20, 2017

Dohmen releases new white paper on improved outsourcing model for orphan drug manufacturers

The $114 billion orphan drug industry is traditionally served by a multi-channel model of disparate service providers. Each claims expertise in a specific niche of services, yet therapy adherence for rare disease patients is just over 58 percent. The Dohmen Life Science Services white paper explores an integrated outsourcing model that’s driving better adherence, supporting healthier outcomes and helping orphan drug manufacturers continuously improve their patient program with lower cost and less risk. Industry experts and patient advocates weigh in on why business process outsourcing must evolve.
learn more
December 20, 2016

Dohmen’s Wendy White named Global Genes Chairman of the Board

Global Genes, one of the world’s leading nonprofit rare disease patient advocacy organizations, recently named Wendy White, Dohmen Life Science Services (DLSS) Senior Vice President, Rare Disease, as the Chairman of the Board.
learn more
November 22, 2016

Dohmen sponsors annual HBA conference helping transform women leadership in healthcare

Dohmen Life Science Services recently joined more than 900 industry leaders at the annual Healthcare Businesswomen’s Association (HBA) conference. As one of three Diamond sponsors, DLSS helped shine light on the importance of women leaders in healthcare.
learn more
November 17, 2016

Twelve months & counting: Are you ready for DSCSA?

Upcoming Drug Supply Chain Security Act (DSCSA) legislation outlines critical steps to identify and trace certain prescription drugs as they are distributed in the United States. The new requirements impact manufacturers, repackagers, wholesalers, dispensers and third-party logistics providers to varying degrees. Pat McGinn, DLSS expert for DSCSA compliance, shares these top 5 tips for manufacturer readiness.
learn more
October 27, 2016

Dohmen announces new Vice President, Quality Assurance Consulting, DLSS Compliance Services

Dohmen has appointed Kimberly Garko, Ph.D., MS, as Vice President of Quality Assurance (QA) Consulting, Compliance Services with Dohmen Life Science Services. Garko will develop and manage QA consulting programs for pharma, biologic and medical device manufacturers to ensure their processes are compliant with industry regulations and standards
learn more
October 25, 2016

Dohmen’s Chief Scientific Officer shares drug development predictions at NORD annual summit

Hundreds gathered this month at NORD’s Rare Diseases and Orphan Products Breakthrough Summit in Arlington, VA. Patients and caregivers joined leaders in the FDA, NIH, industry and payer community to address critical issues in rare disease. Speakers reported on progress in diagnosis, treatment, patient engagement and market access of orphan products. Eric Floyd, PhD, MBA, Chief Science Officer and President of Compliance Services, Dohmen Life Science Services, joined leaders from the NIH and FDA in an afternoon panel, “Predicting the Pipeline – Orphan Product Development and Progress in 2017.”
learn more
October 24, 2016

Dohmen launches new Market Access and Government Program services to help clients maximize revenue and simplify commercial operations

Dohmen Life Science Services is expanding its financial service offerings to now include Market Access and Government Programs. The new services complement the company’s broad capabilities from supply chain and compliance services to patient services and technology.
learn more
October 14, 2016

Dohmen’s patient-centered care model for rare disease featured in PharmaVOICE

PharmaVOICE’s October issue dives deeper into the unique needs of the rare disease patient community and why new care models are driving better financial and clinical outcomes. The article, “Creating a More Efficient, Effective and Easier Model for Patient Care” showcases how empowered patients are calling for a shift away from multi-vendor, disconnected operations, including pharmacy benefit managers, wholesalers, specialty pharmacies and other “hub” service companies
learn more
Next >